A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic
stem cells into the peripheral blood in patients with multiple myeloma.